- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01206218
Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer (BREC-AGC)
September 20, 2010 updated by: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Evaluation of customized treatment according to BRCA1 assessment in patients with advanced gastric cancer
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
96
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of informed consent
- Female or male aged 18 years and over
- Histologic or cytologic confirmation of advanced gastric cancer
- Stage III-IV (AJCC 7th)
- ECOG: 0-2
- Have tumor sample that can be tested for BRCA1 mRNA expression
- Negative pregnancy test for women of childbearing potential
- Neutrophile granulocyte greater than 1.5×10^9/L
- Hemoglobin greater than 10g/dL
- Platelet greater than 100×10^9/L
- Serum bilirubin not greater than 1.5x upper limit of reference range (ULRR)
- ALT or AST not greater than 1.5x ULRR
- Creatinine clearance no less than 60ml/min
Exclusion Criteria:
- Have at least another primary malignant tumor
- Active infection
- Chemotherapy with experimental drug within 3 weeks before the start of study therapy
- Women who are pregnant or breast feeding
- Weight loss greater 10% within 6 weeks before the start of study therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A
FLOT Regimen
|
FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
|
Experimental: Group B
FLO Regimen or FLOT Regimen
|
FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free Survival
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: 12 months
|
12 months
|
Response Rate
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Baorui Liu, MD, PHD, Drum Tower Hospital, Nanjing University Medical School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Anticipated)
October 1, 2012
Study Registration Dates
First Submitted
September 20, 2010
First Submitted That Met QC Criteria
September 20, 2010
First Posted (Estimate)
September 21, 2010
Study Record Updates
Last Update Posted (Estimate)
September 21, 2010
Last Update Submitted That Met QC Criteria
September 20, 2010
Last Verified
September 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BREC-AGC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Gastric Cancer
-
GeneScience Pharmaceuticals Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaboratorsUnknownAdvanced Gastric or Gastroesophageal Junction CancerChina
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction AdenocarcinomaUkraine
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction CancerUnited States
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.RecruitingAdvanced Breast Cancer | Advanced Solid Tumor | Advanced Gastric CancerUnited States
-
Krankenhaus NordwestCompletedAdvanced Gastric Cancer | Advanced Cancer of the Esophagogastric JunctionGermany
-
Huashan HospitalSeattle Integrative Cancer CenterUnknownMetastatic Gastric Cancer | Locally Advanced Gastric CancerChina, United States
-
Astellas Pharma Global Development, Inc.AvailableMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma CancerUnited States, Germany
-
Krankenhaus NordwestCompletedAdvanced Gastric Cancer | Esophagogastric Junction CancerGermany
-
Gruppo Italiano per lo studio dei Carcinomi dell...Regione LombardiaTerminatedMetastatic Gastric Cancer | Locally Advanced Unresectable Gastric CancerItaly
Clinical Trials on FLOT Regimen
-
Henan Cancer HospitalUnknownAdenocarcinoma of the Stomach / GastroesophagealChina
-
Tang-Du HospitalRecruiting
-
Erasmus Medical CenterNot yet recruitingEsophageal Cancer | Adenocarcinoma of the Esophagus
-
Jagiellonian UniversityRecruiting
-
Ruijin HospitalCompletedGastric Cancer | Chemotherapy EffectChina
-
Institut für Klinische Krebsforschung IKF GmbH...Trium Analysis Online GmbHCompletedStomach Cancer | Gastroesophageal Junction CancerGermany
-
Keio UniversityRecruitingEsophageal Squamous Cell CarcinomaJapan
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, GermanyActive, not recruitingGastric Adenocarcinoma | Oesophageal AdenocarcinomaUnited Kingdom
-
Ruijin HospitalCompletedChemotherapy EffectChina
-
Ruijin HospitalNot yet recruitingGastric Cancer | Neoadjuvant ChemotherapyChina